Of the 103 cohort patients, 50 (48.5%) patients received glucocorticoids at admission; 63 (61.2%) patients needed insulin at admission, requiring an average of 29.6 units per 24 h; and 5 (4.9%) patients had documented hypoglycemia (defined as blood glucose level <4 mmol/L) as detected by capillary blood glucose testing during admission (2 patients were on hydroxychloroquine, 4 on insulin, and 1 had end-stage renal disease). The gene discussed is INS; the disease is chronic kidney disease.